Profile
François Meyer formerly worked at Sangamo Therapeutics France SAS, as Chairman & Chief Executive Officer in 2013, Centelion SAS, as Chief Executive Officer, Fonds National de La Recherche, as Chairman-Scientific Council from 2006 to 2010, BioTransplant, Inc., as Director, Systemix, Inc., as Director from 1993 to 1996, Introgen Therapeutics, Inc., as Director, SaviCorp, as Director General in 2006, Gene Therapy Systems, Inc., as Director, Urogene SA, as Director, Aventis Pharma SARL, as Director-Research & Development in 2002, BioSeek, Inc., as Director, Centre National de la Recherche Scientifique, as Director-Research in 1992, Gencell SA (France), as Managing Director, BASF Performance Products Ltd.
(United Kingdom), as Head-Molecular Genetics in 1984, Rhone Poulenc Rorer, as Corporate Senior Vice President-Global Research from 1996 to 2006, Amsterdam Molecular Therapeutics (AMT) Holding NV, as Member-Supervisory Board from 2012 to 2013, Sandoz Pharmaceuticals AG, as Member-Corporate Research Board & Vice President from 1993 to 1996, and uniQure NV, as Member-Supervisory Board from 2010 to 2014.
Dr. Meyer received his doctorate degree in 1978 from the University of Zurich and undergraduate degree in 1972 from Swiss Federal Institute of Technology.
Former positions of François Meyer
Companies | Position | End |
---|---|---|
UNIQURE N.V. | Director/Board Member | 01/01/2014 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Director/Board Member | 11/03/2013 |
Urogene SA
Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Director/Board Member | 17/10/2012 |
Fonds National de La Recherche
Fonds National de La Recherche Miscellaneous Commercial ServicesCommercial Services Fonds National de La Recherche is a private company based in Esch-sur-Alzette, Luxembourg. The Luxembourger company engages in research of science and humanities and research funding activities. It was founded in 1999, and Marc Schiltz has been the CEO of the company since 2011. | Corporate Officer/Principal | 01/01/2010 |
SAVICORP | Chief Executive Officer | 01/01/2006 |
Training of François Meyer
Swiss Federal Institute of Technology | Undergraduate Degree |
University of Zurich | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Private companies | 17 |
---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
BASF Performance Products Ltd. (United Kingdom)
BASF Performance Products Ltd. (United Kingdom) Chemicals: SpecialtyProcess Industries Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom. | Process Industries |
Aventis Pharma SARL
Aventis Pharma SARL Pharmaceuticals: MajorHealth Technology Founded in 1982, Aventis Pharma SARL is a French pharmaceutical company that manufactures pharmaceuticals. Part of Sanofi, the company is based in Antony, France. | Health Technology |
SaviCorp
SaviCorp Movies/EntertainmentConsumer Services SaviCorp is an automotive technology company dedicated to saving the planet, one vehicle, one fleet, at a time. It creates and commercializes blow-by gas and crankcase engine emission reduction technology, which intends to develop and market on a commercial basis. The technology is a relatively simple gasoline and diesel engine emission reduction device that the company intends to sell to its customers for effective and efficient emission reduction and engine efficiency for implementation in both new and presently operating automobiles. The company’s products include Dynovalve, Dynocap, Dynoflo, Dynoplug, Fiber and water. SaviCorp was founded by Serge V. Monros on November 3, 1986 and is headquartered in Santa Ana, CA. | Consumer Services |
Sandoz Pharmaceuticals AG
Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland. | Health Technology |
BioSeek, Inc.
BioSeek, Inc. Miscellaneous Commercial ServicesCommercial Services BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. | Commercial Services |
Gene Therapy Systems, Inc. | |
Urogene SA
Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Commercial Services |
Rhone Poulenc Rorer
Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Process Industries |
Centre National de la Recherche Scientifique
Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | Government |
Sangamo Therapeutics France SAS
Sangamo Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics France SAS is a biotechnology company, which engages in developing platforms for T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases. The company was founded on April 12, 2001, and is headquartered in Valbonne-Sophia Antipolis, France. | Commercial Services |
Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. Medical SpecialtiesHealth Technology Introgen Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company develops molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. The company maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. It was founded in June 1993 and is headquartered in Austin, TX. | Health Technology |
Fonds National de La Recherche
Fonds National de La Recherche Miscellaneous Commercial ServicesCommercial Services Fonds National de La Recherche is a private company based in Esch-sur-Alzette, Luxembourg. The Luxembourger company engages in research of science and humanities and research funding activities. It was founded in 1999, and Marc Schiltz has been the CEO of the company since 2011. | Commercial Services |
Centelion SAS | |
Gencell SA (France)
Gencell SA (France) Hospital/Nursing ManagementHealth Services Part of Sanofi, Gencell SA is a company based in Vitry-sur-Seine, France. The French company operates a cancer treatment center. | Health Services |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
BioTransplant, Inc.
BioTransplant, Inc. Pharmaceuticals: MajorHealth Technology BioTransplant, Inc. is a life science company. The company discovers, develops and commercializes therapeutics, therapeutic devices and therapeutic regimens designed to suppress undesired immune responses and enhance the body's ability to accept donor cells, tissues and organs. The company was founded on March 20, 1990 and is headquartered in Charlestown, MA. | Health Technology |
- Stock Market
- Insiders
- François Meyer